A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

NCT07082452 · clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
262
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris